Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Paris (ots/PRNewswire) - Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% ...